« Previous
Next »
Titles
- M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk1
- Medicaid Fraud Control Units fiscal year 2017 annual report1
- Medicaid eligibility, enrollment, and renewal processes and system study: case study summary report--New York1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Arizona1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Colorado1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Florida1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--Idaho1
- Medicaid eligibility, enrollment, and renewal processes and systems study: case study summary report--North Carolina1
- Medical product communications that are consistent with the FDA-required labeling: questions and answers1
- Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials1
- Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices1
- Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data1
- Methods used to enable interoperability among U.S. non-federal acute care hospitals in 20171
- Microdose radiopharmaceutical diagnostic drugs: nonclinical study recommendations1
- Migraine: developing drugs for acute treatment1
- Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application1